These CRC mapping methods, along with pharmacological and genomic studies, have identified critical roles for MYOD, IRF8, FOXA1, and SOX11 TFs in rhabdomyosarcoma, acute myeloid leukaemia (AML), prostate cancer, and neuroblastoma [22,27,32,33], respectively. This evidence concerns the gene MYOD1 and prostate carcinoma.